• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

193.03 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform
April 07, 2026
From Natera, Inc.
Via Business Wire
News headline image
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
March 31, 2026
From Natera, Inc.
Via Business Wire
News headline image
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
March 16, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
March 12, 2026
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
February 27, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
February 24, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
February 17, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
February 06, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits Signatera™ CDx PMA to FDA
February 02, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
January 28, 2026
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
January 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
January 21, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
January 20, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
January 13, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
January 12, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
January 11, 2026
From Natera, Inc.
Via Business Wire
News headline image
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
January 07, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
January 05, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
January 05, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 22, 2025
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
December 18, 2025
From Natera, Inc.
Via Business Wire
News headline image
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
December 16, 2025
From Natera, Inc.
Via Business Wire
News headline image
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
December 12, 2025
From Natera, Inc.
Via Business Wire
News headline image
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
December 10, 2025
From Natera, Inc.
Via Business Wire
News headline image
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
December 09, 2025
From Natera, Inc.
Via Business Wire
News headline image
Natera Acquires Foresight Diagnostics
December 05, 2025
From Natera, Inc.
Via Business Wire
News headline image
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
December 03, 2025
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
December 02, 2025
From Natera, Inc.
Via Business Wire
News headline image
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
November 19, 2025
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap